GSK’s Head Of Artificial Intelligence Unveils R&D Goals
Executive Summary
GSK’s John Baldoni talks to Scrip in an exclusive interview about taking over the big pharma’s artificial intelligence R&D strategy and the company’s early-stage progress using machine-driven discovery and development methods.
You may also be interested in...
Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies
BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.
Snapshot: July Highlights
A selection of articles you might have missed from July 2020, including exclusive interviews with industry leaders and a review of Q2 financing statistics.
Execs On The Move, July 2020
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports